Lynparza Prolongs Progression-Free Survival, Sustains Quality of Life in Women with BRCA-Mutated Relapsed Ovarian Cancer
News
Women with BRCA-mutated relapsed serous ovarian cancer who received AstraZeneca’s Lynparza (olaparib) as a maintenance therapy after responding to platinum-based chemotherapy took an average 14 months to see their disease progress, compared to 7.3 ... Read more